Cirius Therapeutics is a clinical-stage pharmaceutical company developing azemiglitazone, an insulin sensitizer aimed at treating non-alcoholic steatohepatitis and other diseases linked to insulin resistance, such as Type 2 Diabetes and metabolic dysfunctions associated with obesity. Their approach targets the underlying metabolic disturbances, potentially improving liver health and metabolic outcomes for affected patients.
Funding
Funding not disclosed
Founders
Product
Problem
Non-alcoholic steatohepatitis (NASH), now referred to as metabolic dysfunction-associated steatohepatitis (MASH), and other diseases linked to insulin resistance, such as Type 2 Diabetes and metabolic dysfunctions associated with obesity, lack effective treatments that address the underlying metabolic disturbances. Current therapeutic options often fail to comprehensively improve liver health and metabolic outcomes for affected patients.
Solution
Cirius Therapeutics is developing azemiglitazone, an insulin sensitizer, as a therapeutic intervention for MASH and related metabolic diseases. Azemiglitazone aims to improve liver health and overall metabolic function by targeting the core mechanisms of insulin resistance. This approach has the potential to address the root causes of these conditions, offering a more effective treatment strategy compared to existing options. By modifying metabolism, Cirius Therapeutics seeks to provide innovative therapies for chronic metabolic diseases.
Target Audience
The primary target audience includes patients with MASH, Type 2 Diabetes, and other metabolic disorders linked to insulin resistance, as well as healthcare providers specializing in endocrinology, hepatology, and metabolic diseases.
Features
- Azemiglitazone: A novel insulin sensitizer in clinical development.
- Targets insulin resistance: Addresses the underlying metabolic disturbances in MASH, Type 2 Diabetes, and obesity-related metabolic dysfunctions.
- Potential to improve liver health: Aims to reduce liver inflammation and fibrosis associated with MASH.
- Clinical-stage development: Progressing through clinical trials to evaluate safety and efficacy.